Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1561 to 1575 of 2011 results for nice guidelines

  1. Methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents (TA13)

    This guidance has been replaced by NICE technology appraisal guidance 98 [Replaced by NICE guideline NG87].  

    Withdrawn guidance

  2. Transobturator foramen procedures for stress urinary incontinence (IPG107)

    The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on transobturator foramen procedures for stress incontinence in January 2005. This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG40. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.

    Withdrawn guidance

  3. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

    Medtech innovation briefing
    Published
    24 August 2016

  4. Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

    Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

    Technology appraisal guidance
    Published
    21 February 2024
    View recommendations

    Sections for TA952

  5. Guidance on the use of gemcitabine for the treatment of pancreatic cancer (TA25)

    This guidance has been replaced by NICE guideline NG85.

    Withdrawn guidance

  6. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

    Withdrawn guidance

  7. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

    Withdrawn guidance

  8. The clinical effectiveness and cost effectiveness of sibutramine for obesity (TA31)

    This guidance has been replaced by NICE guideline CG43. 

    Withdrawn guidance

  9. Taxanes for the treatment of breast cancer (TA30)

    This guidance has been replaced by NICE guideline CG81.

    Withdrawn guidance

  10. The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)

    This guidance has been updated and replaced NICE guideline CG38.

    Withdrawn guidance

  11. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Withdrawn guidance

  12. The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)

    This guidance has been updated and replaced by NICE guideline CG43.

    Withdrawn guidance

  13. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

    Withdrawn guidance

  14. Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)

    This guidance has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  15. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10. 

    Withdrawn guidance